*Estimated balance as of 8/10/09, the closing date of latest financing.
‡$34M was received from GSK in the quarter for IDX899 license.
During 2Q09, IDIX closed its drug-discovery office in Caligari, Italy and transferred the scientists there to corporate headquarters in Cambridge, Massachusetts; this will reduce cash burn by $3-4M per year.
If we make the simplifying assumption that the cash burn going forward will be the same as the cash burn during 2Q09, then the $68M estimated cash balance as of 8/10/09 is sufficient to cover five quarters of operations even in the worst-case scenario where there is no up-front cash from new partnership deals.